What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Her primary scientific interests are in Internal medicine, Lung cancer, Oncology, Nivolumab and Carcinoma.
Leora Horn usually deals with Internal medicine and limits it to topics linked to Surgery and Gastroenterology and Adverse effect.
Her work deals with themes such as Hazard ratio, Targeted therapy, Clinical trial and Atezolizumab, which intersect with Lung cancer.
Her research investigates the link between Atezolizumab and topics such as Avelumab that cross with problems in Cancer cell, PD-L1 and Colorectal cancer.
Leora Horn has researched Oncology in several fields, including Survival rate and Pathology.
Her Nivolumab research is multidisciplinary, relying on both Clinical endpoint and Docetaxel.
Her most cited work include:
- Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. (8133 citations)
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer (5007 citations)
- Pembrolizumab for the treatment of non-small cell lung cancer (3324 citations)
What are the main themes of her work throughout her whole career to date?
Her main research concerns Internal medicine, Oncology, Lung cancer, Cancer research and In patient.
Her study in Chemotherapy, Nivolumab, Cancer, non-small cell lung cancer and Docetaxel are all subfields of Internal medicine.
Her research in Nivolumab tackles topics such as Clinical endpoint which are related to areas like Adverse effect.
Her studies in Oncology integrate themes in fields like Pembrolizumab, Atezolizumab, Phases of clinical research, Carboplatin and Bevacizumab.
The various areas that Leora Horn examines in her Lung cancer study include Targeted therapy, Clinical trial, Disease and Carcinoma.
Her Cancer research research focuses on Anaplastic lymphoma kinase and how it connects with Crizotinib.
She most often published in these fields:
- Internal medicine (67.54%)
- Oncology (56.81%)
- Lung cancer (36.13%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (67.54%)
- Oncology (56.81%)
- Lung cancer (36.13%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Internal medicine, Oncology, Lung cancer, Cancer research and In patient.
Her Chemotherapy, Cancer, Adverse effect, Nivolumab and Clinical endpoint study are her primary interests in Internal medicine.
Her studies in Adverse effect integrate themes in fields like Pembrolizumab and Progressive disease.
Leora Horn combines subjects such as Phase i ii, Ipilimumab, Combination therapy and Docetaxel with her study of Nivolumab.
The Oncology study combines topics in areas such as Previously treated, Atezolizumab, Bevacizumab, Cohort and Immunotherapy.
Specifically, her work in Lung cancer is concerned with the study of Non small cell.
Between 2018 and 2021, her most popular works were:
- Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study (238 citations)
- COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. (181 citations)
- First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. (178 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Internal medicine, Lung cancer, Oncology, Clinical trial and Cancer research are her primary areas of study.
Her studies in Randomized controlled trial, Nivolumab, Adverse effect, Chemotherapy and Cancer are all subfields of Internal medicine research.
Her Nivolumab study which covers Clinical endpoint that intersects with Ipilimumab.
Her research integrates issues of Plasma samples, Systemic therapy and Intensive care medicine in her study of Lung cancer.
Her primary area of study in Oncology is in the field of Overall survival.
Her Clinical trial research incorporates elements of Pembrolizumab, Atezolizumab, Carcinoma and Survival rate.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
